Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer pflu?

Executive Summary

Pfizer CEO Hank McKinnell will reschedule his Feb. 4 speech at the National Press Club after coming down with the flu. McKinnell was slated to speak on health care reform, but was likely to have also addressed - either through prepared remarks or during the question and answer session - the cardiovascular safety questions surrounding Pfizer's COX-2 inhibitors Celebrex and Bextra (1"The Pink Sheet" Jan. 3, 2005, p. 17). Pfizer says McKinnell caught the flu while traveling through southern Asia to assess the company's tsunami relief effort...

You may also be interested in...



FDA Issues Caution On COX-2s, But Leaves Open Possibility For First-Line Use

FDA's caution on the use of COX-2 inhibitors leaves open the possibility for patients to use Pfizer's Celebrex and Bextra as first-line therapies

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel